LGM
ADVM

Logos Global Management’s Adverum Biotechnologies ADVM Stock Holding History

Logos Global Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-416,666
Closed -$2.92M – 48
2024
Q3 		$2.92M Hold
416,666
– – 0.32% 48
2024
Q2 		$2.86M Sell
416,666
-1,083,333
-72% -$10.1M 0.23% 51
2024
Q1 		$21.2M Buy
+1,499,999
New +$22.8M 1.72% 19

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Logos Global Management's ADVM Position: Q4 2024 in Review

Logos Global Management sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 416,666 shares — an estimated $2.92M sold.

Logos Global Management first reported a position in ADVM in Q1 2024 and held it in 3 quarters. The position peaked at $21.2M in Q1 2024. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

  • Logos Global Management reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • Logos Global Management sold 416,666 Adverum Biotechnologies shares in Q4 2024, an estimated $2.92M.
  • Logos Global Management first reported a position in Adverum Biotechnologies in Q1 2024 and held it in 3 quarters.
  • Logos Global Management's Adverum Biotechnologies position peaked at $21.2M in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on Logos Global Management's 13F filing for Q4 2024, filed 14 Feb 2025.